1. Home
  2. FNLC vs ACRS Comparison

FNLC vs ACRS Comparison

Compare FNLC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$29.50

Market Cap

306.9M

Sector

Finance

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.18

Market Cap

314.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
ACRS
Founded
1864
2012
Country
US
US
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.9M
314.2M
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
FNLC
ACRS
Price
$29.50
$3.18
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.75
AVG Volume (30 Days)
15.8K
1.4M
Earning Date
04-22-2026
01-01-0001
Dividend Yield
5.12%
N/A
EPS Growth
N/A
N/A
EPS
2.16
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.11
$1.05
52 Week High
$30.33
$4.89

Technical Indicators

Market Signals
Indicator
FNLC
ACRS
Relative Strength Index (RSI) 57.75 44.06
Support Level $28.88 $3.33
Resistance Level $29.71 $3.78
Average True Range (ATR) 0.72 0.25
MACD 0.02 -0.08
Stochastic Oscillator 64.29 6.54

Price Performance

Historical Comparison
FNLC
ACRS

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: